BioInformant Goes Behind the Scenes at FUJIFILM Irvine Scientific
Dec 06, 2019| Posted in Bioproduction, Cell & Gene Therapy, Cell Culture, Corporate
FUJIFILM Irvine Scientific CEO Yutaka Yamaguchi interviewed by Bioinformant
Yutaka Yamaguchi, CEO of FUJIFILM Irvine Scientific, was recently invited to sit down with Cade Hildreth, CEO of BioInformant—the world’s largest publisher of stem cell industry news. The two discussed a breadth of topics, including the changes that becoming part of Fujifilm has brought to the organization.
Diving into a variety of topics, such as the reasons for Fujifilm's acquisition of Irvine Scientific, the importance of the company’s dual manufacturing facilities, the traits that differentiate us from competitors, and trends within the Regenerative Medicine industry at large, the wide-ranging interview offered valuable insights into both Yamaguchi and Fujifilm’s plans for the future.
In discussing FUJIFILM Irvine Scientific, Yamaguchi covered his background, as well as the organization's, prior to the acquisition by Fujifilm. For BioInformant readers, the discussion offered information regarding product offerings for the myriad of markets that FUJIFILM Irvine Scientific serves, as well as what about our culture sets us apart: Industry Expertise, Partnership, and Service.
"We provide unparalleled service and regulatory support," said Yamaguchi. "As medical device manufacturers, we have extensive experience working with regulatory bodies worldwide. This knowledge is shared with our biopharmaceutical and cell therapy customers to help them meet regulatory requirements for their therapeutics."
The article concluded by discussing the opportunities that Fujifilm's investment has provided to our organization since the acquisition, as well as Yamaguchi's five-year plan for growing the company as an industry leader across all business lines.
Interested in learning how our diverse portfolio of advanced cell culture media solutions can support your unique applications? Contact us today to get started.